Topic : TKIs

Other Topics :

ASCO 2015: Not everyone reaps the benefits of TKIs

Report from the American Society of Clinical Oncology (ASCO), Chicago IL, May 29-June 2, 2015 – Tyrosine kinase inhibitors (TKIs) have changed the face of treatment, transforming CML into a manageable illness where once it was deadly. But two studies presented at ASCO 2015 sugge
Continue Reading →

ASCO 2015: Need for speed when it comes to treatment response

When starting treatment with a TKI, achieving an early response to medication bodes well for future success. If a medication can suppress leukemia cells quickly, it’s less likely that other mutations will emerge.
Continue Reading →

ASCO 2015: What do you think about taking a CML medication?

Two questions were posed in a web-based survey of people enrolled in an online community called the Cancer Experience Registry: CML (Buzaglo and colleagues. ASCO 2015; abstract 9558).
Continue Reading →

What is “treatment resistance”? – Part 2

As we saw in Part 1, a small number of people will be resistant to Gleevec from the outset (called “primary resistance”), and different therapies are needed to get their disease under control.
Continue Reading →

What is “treatment resistance”?

Part 1 When a person first starts treatment for CML, an obvious concern is whether the medication will work. Will CML respond, or is your body somehow resistant to the TKI (tyrosine kinase inhibitor)? But what does “treatment resistance” mean, and what can be done about it?
Continue Reading →

Achieving a faster response to treatment

A number of studies have shown that people taking a second-generation medication, such as Sprycel or Tasigna, can reach key treatment milestones earlier than if they start treatment with Gleevec.
Continue Reading →

CML Radio: Your Top Questions – Part 2

CML-IQ is pleased to announce CML radio – featuring news, views and insights about chronic myelogenous leukemia. In part 2, our panel of CML nurses address common questions people have after living with CML for a few years.
Continue Reading →

CML Radio: Your Top Questions

In Part 1, the CML nurses talk about the questions people have when they are first diagnosed: Why me? Can CML be cured? And what can I do now?
Continue Reading →

10 years after starting treatment

The CML-study IV group has been looking at different ways of treating CML. For example, the group found that higher doses of Gleevec could enable people to achieve key milestones...
Continue Reading →

Switching meds: TIDEL-II results

A review of the TIDEL-II study that compares the efficacy of increasing the dose of Gleevec versus switching to a second-generation TKI when your response is not satisfactory.
Continue Reading →